Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
22 hedge funds and large institutions have $29.1M invested in Evofem Biosciences, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
+$8.99M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$7.13M |
| 3 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
+$3.69M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.31M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$1.63M |
Top Sellers
EVFM Hedge Fund Activity: Q4 2014 in Review
22 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2014, worth a combined $29.1M.
Buyers outnumbered sellers: 22 funds opened new EVFM positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Clarus Ventures, opening a new position worth an estimated $8.99M.
- 22 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $29.1M of Evofem Biosciences, Inc. Common Stock stock for Q4 2014.
- 22 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2014 and 0 closed out, a net change of +22 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2014 was Clarus Ventures, an estimated $8.99M added.
Based on aggregated 13F filings for Q4 2014.